Intellectus Partners’s AbbVie ABBV Stock Holding History

Intellectus Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-600	Closed	-$1K	–	581
2018 Q1	$1K	Buy	+600	New	+$65.9K	﹤0.01%	573

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Intellectus Partners's ABBV Position: Q2 2026 in Review

Intellectus Partners increased its AbbVie (ABBV) stake by 7.5% in Q2 2026, buying an estimated $174K and bringing the position to 11,595 shares worth $2.92M. The position accounts for 0.5% of the portfolio, ranked #42.

Intellectus Partners first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Intellectus Partners held 11,595 shares of AbbVie worth $2.92M as of Q2 2026.
Intellectus Partners bought 811 AbbVie shares in Q2 2026, an estimated $174K.
AbbVie made up 0.5% of Intellectus Partners's portfolio in Q2 2026, its #42 holding.
Intellectus Partners first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.